Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
1,590 questions in 129 reviews · Gynaecological, Neuro-oncology and Orphan Cancer
current versionsNo studies 281 · 17.7%Ungraded 74 · 4.7%Very low 410 · 25.8%Low 420 · 26.4%Moderate 280 · 17.6%High 125 · 7.9%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Chemoradiotherapy vs radical surgery Recurrence · women (18 years and older) diagnosed with stage IB2 cervical cancer Type II or type III radical hysterectomy compared to chemoradiotherapy as a primary intervention for stage… (2018) · Cochrane | OR 2.26 [1.24, 4.14] | 1 study · 215 participants | Very low |
Chemoradiotherapy vs radical surgery Adverse events: lymphoedema · women (18 years and older) diagnosed with stage IB2 cervical cancer Type II or type III radical hysterectomy compared to chemoradiotherapy as a primary intervention for stage… (2018) · Cochrane | no estimate extracted | NR | No studies |
Bevacizumab vs placebo Reduction in oedema (T2 hyperintensity) · people previously treated with radiosurgery or fractionated radiotherapy to the brain or head and neck region with a… Interventions for the treatment of brain radionecrosis after radiotherapy or radiosurgery (2018) · Cochrane | no estimate extracted | 1 study · 14 participants | Low |
Edaravone plus corticosteroids vs corticosteroids Change in neurocognitive function · people previously treated with radiosurgery or fractionated radiotherapy to the brain or head and neck region with a… Interventions for the treatment of brain radionecrosis after radiotherapy or radiosurgery (2018) · Cochrane | no estimate extracted | NR | No studies |
Edaravone plus corticosteroids vs corticosteroids Severe adverse events · people previously treated with radiosurgery or fractionated radiotherapy to the brain or head and neck region with a… Interventions for the treatment of brain radionecrosis after radiotherapy or radiosurgery (2018) · Cochrane | no estimate extracted | 1 study · 137 participants | Low |
Edaravone plus corticosteroids vs corticosteroids Quality of life · people previously treated with radiosurgery or fractionated radiotherapy to the brain or head and neck region with a… Interventions for the treatment of brain radionecrosis after radiotherapy or radiosurgery (2018) · Cochrane | no estimate extracted | NR | No studies |
Edaravone plus corticosteroids vs corticosteroids Corticosteroid requirements · people previously treated with radiosurgery or fractionated radiotherapy to the brain or head and neck region with a… Interventions for the treatment of brain radionecrosis after radiotherapy or radiosurgery (2018) · Cochrane | no estimate extracted | NR | No studies |
Bevacizumab vs placebo Reduction in post‐gadolinium enhancement · people previously treated with radiosurgery or fractionated radiotherapy to the brain or head and neck region with a… Interventions for the treatment of brain radionecrosis after radiotherapy or radiosurgery (2018) · Cochrane | no estimate extracted | 1 study · 14 participants | Low |
Bevacizumab vs placebo Reduction in neurological/clinical symptoms/severity · people previously treated with radiosurgery or fractionated radiotherapy to the brain or head and neck region with a… Interventions for the treatment of brain radionecrosis after radiotherapy or radiosurgery (2018) · Cochrane | no estimate extracted | 1 study · 14 participants | Very low |
Bevacizumab vs placebo Severe adverse events · people previously treated with radiosurgery or fractionated radiotherapy to the brain or head and neck region with a… Interventions for the treatment of brain radionecrosis after radiotherapy or radiosurgery (2018) · Cochrane | no estimate extracted | 1 study · 14 participants | Low |
Bevacizumab vs placebo Quality of life · people previously treated with radiosurgery or fractionated radiotherapy to the brain or head and neck region with a… Interventions for the treatment of brain radionecrosis after radiotherapy or radiosurgery (2018) · Cochrane | no estimate extracted | NR | No studies |
Bevacizumab vs placebo Corticosteroid requirements · people previously treated with radiosurgery or fractionated radiotherapy to the brain or head and neck region with a… Interventions for the treatment of brain radionecrosis after radiotherapy or radiosurgery (2018) · Cochrane | no estimate extracted | NR | No studies |
Edaravone plus corticosteroids vs corticosteroids Reduction in oedema (T2 hyperintensity) · people previously treated with radiosurgery or fractionated radiotherapy to the brain or head and neck region with a… Interventions for the treatment of brain radionecrosis after radiotherapy or radiosurgery (2018) · Cochrane | MD 3.03 | 1 study · 137 participants | Low |
Edaravone plus corticosteroids vs corticosteroids Reduction in post‐gadolinium enhancement · people previously treated with radiosurgery or fractionated radiotherapy to the brain or head and neck region with a… Interventions for the treatment of brain radionecrosis after radiotherapy or radiosurgery (2018) · Cochrane | MD 0.47 | 1 study · 137 participants | Low |
Edaravone plus corticosteroids vs corticosteroids Improvement in LENT/SOMA · people previously treated with radiosurgery or fractionated radiotherapy to the brain or head and neck region with a… Interventions for the treatment of brain radionecrosis after radiotherapy or radiosurgery (2018) · Cochrane | OR 2.51 | 1 study · 137 participants | Low |
Surgery plus whole brain radiotherapy (WBRT) vs stereotactic radiosurgery Overall survival · people with single or solitary brain metastasis Surgery versus stereotactic radiotherapy for people with single or solitary brain metastasis (2018) · Cochrane | HR 0.92 [0.48, 1.77] | 1 study · 64 participants | Very low |
Surgery plus whole brain radiotherapy (WBRT) vs stereotactic radiosurgery plus WBRT Quality of life (HRQoL) · people with single or solitary brain metastasis Surgery versus stereotactic radiotherapy for people with single or solitary brain metastasis (2018) · Cochrane | no estimate extracted | 1 study · 14 participants | Very low |
Surgery plus whole brain radiotherapy (WBRT) vs stereotactic radiosurgery Adverse events · people with single or solitary brain metastasis Surgery versus stereotactic radiotherapy for people with single or solitary brain metastasis (2018) · Cochrane | RR 0.31 [0.07, 1.44] | 1 study · 64 participants | Very low |
Surgery plus whole brain radiotherapy (WBRT) vs stereotactic radiosurgery Adverse events (moderate) · people with single or solitary brain metastasis Surgery versus stereotactic radiotherapy for people with single or solitary brain metastasis (2018) · Cochrane | RR 0.62 [0.11, 3.5] | 1 study · 64 participants | Very low |
Surgery plus whole brain radiotherapy (WBRT) vs stereotactic radiosurgery Adverse events (severe) · people with single or solitary brain metastasis Surgery versus stereotactic radiotherapy for people with single or solitary brain metastasis (2018) · Cochrane | RR 0.13 [0, 2.5] | 1 study · 64 participants | Very low |
Surgery plus whole brain radiotherapy (WBRT) vs stereotactic radiosurgery Progression‐free survival: not measured · people with single or solitary brain metastasis Surgery versus stereotactic radiotherapy for people with single or solitary brain metastasis (2018) · Cochrane | no estimate extracted | NR | No studies |
Surgery plus whole brain radiotherapy (WBRT) vs stereotactic radiosurgery Quality of life (HRQoL) · people with single or solitary brain metastasis Surgery versus stereotactic radiotherapy for people with single or solitary brain metastasis (2018) · Cochrane | no estimate extracted | 1 study · 1 participants | Very low |
Surgery plus whole brain radiotherapy (WBRT) vs stereotactic radiosurgery plus WBRT Overall survival · people with single or solitary brain metastasis Surgery versus stereotactic radiotherapy for people with single or solitary brain metastasis (2018) · Cochrane | HR 0.53 [0.2, 1.42] | 1 study · 21 participants | Low |
Surgery plus whole brain radiotherapy (WBRT) vs stereotactic radiosurgery plus WBRT Adverse events (moderate) · people with single or solitary brain metastasis Surgery versus stereotactic radiotherapy for people with single or solitary brain metastasis (2018) · Cochrane | RR 0.37 [0.05, 2.98] | 1 study · 21 participants | Very low |
Surgery plus whole brain radiotherapy (WBRT) vs stereotactic radiosurgery plus WBRT Progression‐free survival · people with single or solitary brain metastasis Surgery versus stereotactic radiotherapy for people with single or solitary brain metastasis (2018) · Cochrane | RR 0.55 [0.22, 1.38] | 1 study · 21 participants | Low |
The effects of an exercise intervention vs a usual care control group with people with cancer undergoing multimodal treatment? Physical fitness · People with cancer undergoing multimodal treatment including surgery Exercise interventions for people undergoing multimodal cancer treatment that includes surgery (2018) · Cochrane | no estimate extracted | 2 studies · 381 participants | Low |
The effects of an exercise intervention vs a usual care control group with people with cancer undergoing multimodal treatment? Safety · People with cancer undergoing multimodal treatment including surgery Exercise interventions for people undergoing multimodal cancer treatment that includes surgery (2018) · Cochrane | no estimate extracted | 8 studies · 507 participants | Low |
The effects of an exercise intervention vs a usual care control group with people with cancer undergoing multimodal treatment? HRQoL · People with cancer undergoing multimodal treatment including surgery Exercise interventions for people undergoing multimodal cancer treatment that includes surgery (2018) · Cochrane | no estimate extracted | 3 studies · 472 participants | Moderate |
The effects of an exercise intervention vs a usual care control group with people with cancer undergoing multimodal treatment? Fatigue · People with cancer undergoing multimodal treatment including surgery Exercise interventions for people undergoing multimodal cancer treatment that includes surgery (2018) · Cochrane | no estimate extracted | 3 studies · 449 participants | Moderate |
The effects of an exercise intervention vs a usual care control group with people with cancer undergoing multimodal treatment? Postoperative outcome · People with cancer undergoing multimodal treatment including surgery Exercise interventions for people undergoing multimodal cancer treatment that includes surgery (2018) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
Extended‐field radiotherapy vs pelvic radiotherapy Overall survival Extended‐field radiotherapy for locally advanced cervical cancer (2018) · Cochrane | HR 0.67 [0.48, 0.94] | 1 study · 337 participants | Moderate |
Extended‐field chemoradiotherapy vs pelvic chemoradiotherapy Overall survival Extended‐field radiotherapy for locally advanced cervical cancer (2018) · Cochrane | HR 0.37 [0.14, 0.96] | 1 study · 74 participants | Very low |
Extended‐field chemoradiotherapy vs pelvic chemoradiotherapy Para‐aortic lymph node recurrence Extended‐field radiotherapy for locally advanced cervical cancer (2018) · Cochrane | RR 0.19 [0.02, 1.54] | 1 study · 74 participants | Very low |
Extended‐field chemoradiotherapy vs pelvic chemoradiotherapy Progression‐free survival Extended‐field radiotherapy for locally advanced cervical cancer (2018) · Cochrane | HR 0.25 [0.07, 0.87] | 1 study · 74 participants | Very low |
Extended‐field chemoradiotherapy vs pelvic chemoradiotherapy Acute adverse events Extended‐field radiotherapy for locally advanced cervical cancer (2018) · Cochrane | RR 0.95 [0.2, 4.39] | 1 study · 74 participants | Very low |
Extended‐field chemoradiotherapy vs pelvic chemoradiotherapy Late adverse events Extended‐field radiotherapy for locally advanced cervical cancer (2018) · Cochrane | RR 0.95 [0.06, 14.59] | 1 study · 74 participants | Very low |
Extended‐field radiotherapy vs pelvic radiotherapy Para‐aortic lymph node recurrence Extended‐field radiotherapy for locally advanced cervical cancer (2018) · Cochrane | RR 0.36 [0.18, 0.7] | 2 studies · 477 participants | Moderate |
Extended‐field radiotherapy vs pelvic radiotherapy Progression‐free survival Extended‐field radiotherapy for locally advanced cervical cancer (2018) · Cochrane | HR 0.92 [0.69, 1.22] | 1 study · 377 participants | Moderate |
Extended‐field radiotherapy vs pelvic radiotherapy Adverse events Extended‐field radiotherapy for locally advanced cervical cancer (2018) · Cochrane | RR 1.05 [0.79, 1.41] | 2 studies · 776 participants | Moderate |
Extended‐field radiotherapy vs pelvic chemoradiotherapy Overall survival Extended‐field radiotherapy for locally advanced cervical cancer (2018) · Cochrane | HR 0.5 [0.39, 0.64] | 1 study · 389 participants | Moderate |
Extended‐field radiotherapy vs pelvic chemoradiotherapy Para‐aortic lymph node recurrence Extended‐field radiotherapy for locally advanced cervical cancer (2018) · Cochrane | RR 0.44 [0.2, 0.99] | 1 study · 389 participants | Low |
Extended‐field radiotherapy vs pelvic chemoradiotherapy Progression‐free survival Extended‐field radiotherapy for locally advanced cervical cancer (2018) · Cochrane | HR 0.52 [0.37, 0.72] | 1 study · 389 participants | Moderate |
Extended‐field radiotherapy vs pelvic chemoradiotherapy Acute adverse events Extended‐field radiotherapy for locally advanced cervical cancer (2018) · Cochrane | RR 0.05 [0.02, 0.11] | 1 study · 388 participants | Moderate |
Extended‐field radiotherapy vs pelvic chemoradiotherapy Late adverse events Extended‐field radiotherapy for locally advanced cervical cancer (2018) · Cochrane | RR 1.06 [0.69, 1.62] | 1 study · 386 participants | Moderate |
Risk‐reducing salpingo‐oophorectomy (RRSO) vs no RRSO Overall survival: BRCA1 or BRCA2 Risk‐reducing bilateral salpingo‐oophorectomy in women with BRCA1 or BRCA2 mutations (2018) · Cochrane | HR 0.32 [0.19, 0.54] | 3 studies · 2548 participants | Very low |
Risk‐reducing salpingo‐oophorectomy (RRSO) vs no RRSO according to BRCA mutation status HGSC mortality: BRCA1 only Risk‐reducing bilateral salpingo‐oophorectomy in women with BRCA1 or BRCA2 mutations (2018) · Cochrane | HR 0.1 [0.02, 0.41] | 2 studies · 1983 participants | Very low |
Risk‐reducing salpingo‐oophorectomy (RRSO) vs no RRSO according to BRCA mutation status HGSC mortality: BRCA2 only Risk‐reducing bilateral salpingo‐oophorectomy in women with BRCA1 or BRCA2 mutations (2018) · Cochrane | no estimate extracted | 2 studies · 1983 participants | Very low |
Risk‐reducing salpingo‐oophorectomy (RRSO) vs no RRSO according to BRCA mutation status Breast cancer mortality: BRCA1 only Risk‐reducing bilateral salpingo‐oophorectomy in women with BRCA1 or BRCA2 mutations (2018) · Cochrane | HR 0.45 [0.3, 0.67] | 4 studies · 2203 participants | Very low |
Risk‐reducing salpingo‐oophorectomy (RRSO) vs no RRSO according to BRCA mutation status Breast cancer mortality: BRCA2 only Risk‐reducing bilateral salpingo‐oophorectomy in women with BRCA1 or BRCA2 mutations (2018) · Cochrane | HR 0.88 [0.42, 1.87] | 3 studies · 5882 participants | Very low |
Risk‐reducing salpingo‐oophorectomy (RRSO) vs no RRSO according to BRCA mutation status Quality of life (ovarian cancer risk perception): BRCA1 only Risk‐reducing bilateral salpingo‐oophorectomy in women with BRCA1 or BRCA2 mutations (2018) · Cochrane | no estimate extracted | 1 study · 98 participants | Very low |